食管癌分期与治疗的共识、争议和建议  

Current consensus and controversy of staging and treatment for esophageal cancer

作　　者：毛友生[1] 赫捷[1] 程贵余[1] 张汝刚[1] 

机构地区：[1]中国医学科学院北京协和医学院肿瘤医院胸外科,北京100021

出　　处：《中国癌症杂志》2011年第7期511-517,共7页China Oncology

摘　　要：目前食管癌的治疗模式仍是以外科为主的综合治疗。但到目前为止,仍在食管癌分期、手术治疗模式选择、手术入路选择、淋巴结清扫方式、术前和术后辅助治疗等方面存在较多争议,本文在复习大量国内外临床研究文献之后,对上述各问题不同观点进行了总结和评述,依据目前的临床循证医学证据形成了一些共识,并对仍有争议之处提出了未来需要进一步研究的相关建议。Currently surgery-oriented multimodality treatment is still the major treatment for esophageal cancer.However,different points of view exist in the staging,treatment modality selection,surgical approach selection,lymphadenectomy,pre-and postoperative adjuvant treatment regimens selection,along with many others.This review made a conclusion and formed some consensus on the above problems based on the evidences reported in the clinical trials,and also provided the suggestion to solve the problems through further conduction of clinical trials.

关 键 词：食管癌 分期 外科治疗 放疗 化疗 

分 类 号：R735.1[医药卫生—肿瘤]